**Supplemental table 1:** Characteristics of 139 patients who did not undergo metastasectomy.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ***At diagnosis of primary RCC*** | | |  |  |
| Male | |  | 92/139 | *66%* |
| Age (median, IQ range) | | | 62 (55-68) |  |
| T-stage | | T1 | 22/139 | *16%* |
|  | | T2 | 22/139 | *16%* |
|  | | T3 | 89/139 | *64%* |
|  | | T4 | 6/139 | *4%* |
| Lymph node positive | | | 29/99 | *29%* |
| Synchronous metastases | | | 76/139 | *55%* |
| Fuhrman grade | | 1 | 1/138 | *1%* |
|  | | 2 | 6/138 | *4%* |
|  | | 3 | 44/138 | *32%* |
|  | | 4 | 87/138 | *63%* |
| Sarcomatoid component  compoponent dedifferentation | | | 36/127 | *28%* |
| ***At start of systemic therapy*** | | |  |  |
| Metastases | | 1 | 23/139 | *17%* |
| 2 | 50/139 | *36%* |
| ≥3 | 66/139 | *47%* |
| Organs affected | | 1 | 23/139 | *17%* |
|  | | 2 | 51/139 | *37%* |
|  | | ≥3 | 65/139 | *47%* |
| Site | | lymph nodes | 84/139 | *60%* |
|  | | lung | 102/139 | *73%* |
|  | | liver | 31/139 | *22%* |
|  | | brain | 5/139 | *4%* |
|  | | kidney/local | 21/139 | *15%* |
|  | | adrenal | 19/139 | *14%* |
|  | | pancreas | 9/139 | *6%* |
|  | | bone | 64/139 | *46%* |
|  | | other | 42/139 | *30%* |
| KPS < 80% | | | 28/128 | *22%* |
| Anemia | |  | 82/132 | *62%* |
| Elevated neutrophils | | | 73/131 | *56%* |
| Elevated platelets | | | 16/131 | *12%* |
| Hypercalcemia | | | 28/122 | *23%* |
| Elevated CRP | | | 99/131 | *76%* |
| LDH > 1.5 ULN | | | 6/128 | *5%* |
| <12mo to systemic therapy | | | 85/138 | *62%* |
| IMDC risk group | Good | | 12/130 | *9%* |
|  | Intermediate | | 79/130 | *61%* |
|  | Poor | | 39/130 | *30%* |

KPS = Karnofsky performance status; Anemia = hemoglobin < 14g/dl (men) or 12.5g/dl (women); ULN neutrophils = 4.500/µl; ULN platelets = 450.000/µl; ULN albumin-corrected calcium = 2.55mmol/l; CRP = c-reactive protein; ULN CRP= 5mg/l; LDH = lactate dehydrogenase; ULN = upper limit of normal.